Study Finds CtDNA Testing For Minimal Residual Disease Can Cut Costs By 21% For Health Plans When Used For Stage II Colorectal Cancer Treatment Decisions
Study Finds CtDNA Testing For Minimal Residual Disease Can Cut Costs By 21% For Health Plans When Used For Stage II Colorectal Cancer Treatment Decisions
研究發現，用於第二階段結直腸癌治療決策時，針對最小殘留疾病的ctDNA檢測可以將健康計劃的成本降低21％
Study Finds CtDNA Testing For Minimal Residual Disease Can Cut Costs By 21% For Health Plans When Used For Stage II Colorectal Cancer Treatment Decisions
研究發現，在治療II期結腸直腸癌時，最小殘留疾病的CtDNA測試可以使健康計劃成本降低21%。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。